Founded in 2019, NewAmsterdam Pharma is a clinical stage company focused on the research and development of transformative therapies for cardio-renal diseases. Its mission is to improve patient care in populations where traditional therapies are not tolerated or have been unsuccessful.
Total raised: $377.6M
Investors 8
| Date | Name | Website |
| - | Population... | population... |
| 18.08.2021 | BioGenerat... | biogenerat... |
| - | Forbion | forbion.co... |
| 04.12.2022 | Panacea Ve... | panaceaven... |
| - | Frazier Li... | frazierls.... |
| - | JVC Invest... | jvcmanagem... |
| 14.12.2022 | Bain Capit... | baincapita... |
| 30.03.2021 | Life Scien... | lspvc.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 05.06.2023 | - | $181.6M | - |
| 14.01.2021 | Series A | $196M | - |
Mentions in press and media 14
| Date | Title | Description |
| 16.12.2024 | Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg | – Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies with high statistical significance (p |
| 29.07.2024 | Menarini Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Efficacy, Safety and Tolerability of Obicetrapib in Patients with Heterozygous Familial Hypercholestero... | -- Achieved primary endpoint of LS mean reduction in LDL-C on top of maximally tolerated lipid modifying therapies at week 12 with statistically significant reduction (p |
| 21.05.2024 | Forbion leads $65 million Series A Financing of Progentos Therapeutics | • Forbion led the Series A financing to support the development of Progentos’ lead program in multiple sclerosis along with additional pipeline programs • Progentos Therapeutics is developing novel small molecules to induce de-novo remyelin... |
| 16.05.2024 | enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors | BOSTON & MONTREAL – enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder c... |
| 02.05.2024 | Forbion Portfolio Company Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer | • Latest deal marks the fifth Forbion portfolio company to be acquired for over $1 bn within a year Naarden, The Netherlands, 2 May 2024 - Forbion portfolio company Mariana Oncology (Mariana) is to be acquired by Novartis for $1 billion in ... |
| 22.04.2024 | Forbion co-leads $75m Series B Financing in SynOx Therapeutics | •Financing co-led by Forbion, HealthCap and new investor Bioqube Ventures •Funds will be used for pivotal trial of potential best-in-class, next-generation treatment for Tenosynovial Giant Cell Tumour Dublin, Ireland and Oxford, UK, 22 Apri... |
| 12.03.2024 | NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD | - |
| 12.03.2024 | NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD | -- TANDEM is designed to evaluate obicetrapib and ezetimibe fixed-dose combination (“FDC”) as an adjunct to diet and maximally tolerated lipid lowering therapy in patients with HeFH, ASCVD or ASCVD risk equivalents requiring additional lowe... |
| 13.02.2024 | NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants | NAARDEN, the Netherlands and MIAMI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines f... |
| 26.08.2023 | Blooming Innovation: 15 Cutting-Edge Biotechnology Startups in The Netherlands | Table of Contents show 1 Introduction 2 New Amsterdam Pharma: Revolutionizing Cardio-Metabolic Therapies 3 The Protein Brewery: Crafting Sustainable, Animal-Free Proteins 4 Epify: Transforming Healthcare with Collaborative Innovation 5... |
Show more